IP6 in cancer therapy: Past, present and future

Current Cancer Therapy Reviews

Volumn 6, Issue 1, 2010, Pages 1-12

  Matejuk, Agata ^a   Shamsuddin, Abulkalam ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer chemotherapy; Inositol; IP6; Nutraceuticals; Nutritional supplement; Phytate

Indexed keywords

DOXORUBICIN; INOSITOL; INOSITOL 1,3,4 TRISPHOSPHATE KINASE; IRINOTECAN; PHOSPHOTRANSFERASE; PHYTIC ACID; TAMOXIFEN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOMA; CANCER PREVENTION; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; DNA REPAIR; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENTIATION; FIBROSARCOMA; HUMAN; LARYNX CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SKIN CANCER; SKIN PAPILLOMA; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; UTERINE CERVIX CANCER;

EID: 77949883130     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410790596443     Document Type: Review

References (153)

1. Scherer J. Ueber eine neue, aus dem Muskelfleische gewonnene Zuckerart. Liebigs Ann Chem 1850; 73: 322-8..
2. Sasakawa N, Sharif M, Hanley MR. Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. Biochem Pharmacol 1995; 50: 137-46.
3. Wilson HC, Bielinska M, Nicholas P, Majerus PW, Wilson DB. Neural tube defects in mice with reduced levels of inositol 1,3,4, - trisphosphate 5/6-kinase. Proc Am Assoc Cancer Res 2009; 106(24): 9831-5.
4. Harland BF, Oberleas D. Phytate in foods. World Rev Nutr Diet 1987; 52: 235-59.
5. O'Dell BL. Dietary factors that affect biological availability of trace elements. Annals of the New York Academy of Sciences 1972; 199: 70-81.
6. Lott G, Batten Mechanisms and regulation of mineral nutrient storage during seed development. In: Kigel J, Galili G, Eds. Seed development and germination. New York: Marcel Dekker 1995; pp. 215-35.
7. Reddy NR, Sathe SK, Salunkhe DK. Phytates in legumes and cereals. Adv Food Res 1982; 28: 1-92.
8. Berridge MJ, Irvine RF. Inositol phosphates and cell signalling. Nature 1989; 341: 197-205.
9. Menniti FS, Oliver KG, Putney JW, Jr, Shears SB. Inositol phosphates and cell signaling: new views of InsP5 and InsP6. Trends Biochem Sci 1993; 18: 53-6.
10. Nagata E, Luo HR, Saiardi A, Bae BI, Suzuki N, Snyder SH. Inositol hexakisphosphate kinase-2, a physiologic mediator of cell death. J Biol Chem 2005; 280: 1634-40.
11. Seeds AM, Bastidas RJ, York JD. Molecular definition of a novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae. J Biol Chem 2005; 280: 27654-61.
12. Shamsuddin A. Cell signaling properties of inositol hexaphosphates. Rimbach G, Packer L, Eds. Nutrigenomics: the role of oxidants and antioxidants in gene expression. New York, NY: Marcel Dekker Inc., 2005; pp. 397-420.
13. Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med 1990; 8: 61-9.
14. Huisamen B, Lochner A. Inositolpolyphosphates and their binding proteins--a short review. Mol Cell Biol 1996; 157: 229-32.
15. Shears SB. Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates: novel effects on ion channels and protein traffic. Sub-Cell Biochem 1996; 26: 187-226.
16. 2+ channel activity by inositol hexakisphosphate. Science 1997; 278: 471-4.
17. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000; 21: 2225-35.
18. 2+-mediated exocytosis of insulin by activation of protein kinase C. Proc Natl Acad Sci USA 1997; 94: 4435-9.
19. Ji H, Sandberg K, Baukal AJ, Catt KJ. Metabolism of inositol pentakisphosphate to inositol hexakisphosphate in Xenopus laevis oocytes. J Biol Chem1989; 264: 20185-8.
20. York JD, Odom AR, Murphy R, Ives EB, Wente SR. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 1999; 285: 96-100.
21. Hanakahi LA, Bartlet-Jones M, Chappell C, Pappin D, West SC. Binding of inositol phosphate to DNA-PK and stimulation of double-strand break repair. Cell 2000; 102: 721-9.
22. Ma Y, Lieber MR. Binding of inositol hexakisphosphate (IP6) to Ku but not to DNA-PKcs. J Biol Chem 2002; 277: 10756-9.
23. Macbeth MR, Schubert HL, Vandemark AP, Lingam AT, Hill CP, Bass BL. Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 2005; 309: 1534-9.
24. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133: 3778S-84S.
25. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum antineoplastic agent: a systematic review. Complement Ther Med 2002; 10: 229-34.
26. Shamsuddin AM. Inositol phosphates have novel anticancer function. J Nutr 1995; 125: 725S-32S.
27. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci 1997; 61: 343-54.
28. Slavin J. Why whole grains are protective; biological mechanisms. In: Proceedings of the Nutrition Society 2003; Vol 62: pp. 129-34.
29. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer 1971; 28: 3-13.
30. Doll R. The geographical distribution of cancer. Br J Cancer 1969; 23: 1-8.
31. Baghurst PA, Rohan TE. High-fiber diets and reduced risk of breast cancer. Int J Cancer 1994; 56: 173-6.
32. Rose DP. Dietary fiber and breast cancer. Nutr Cancer 1990; 13: 1-8.
33. Peters U, Sinha R, Chatterjee N, et al. Prostate LCaOCSTPT. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme.[see comment]. Lancet 2003; 361: 1 491-5.
34. Bingham SA, Day NE, Luben R, et al. European Prospective Investigation into cancer and nutrition. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361: 1496-501, [see comment][Erratum appears in Lancet. 2003 Sep 20; 362(9388): 1000].
35. Larsson SC, Giovannucci E, Bergkvist L, Wolk A. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women. Br J Cancer 2005; 92: 1803-7.
36. Duncan AM. The role of nutrition in the prevention of breast cancer. AACN Clin Issues 2004; 15: 119-35.
37. Ferguson LR, Harris PJ. Protection against cancer by wheat bran: role of dietary fibre and phytochemicals. Eur J Cancer Prev 1999; 8: 17-25.
38. Graf E, Eaton JW. Dietary suppression of colonic cancer: fiber or phytate? Cancer 1985; 56: 717-8.
39. Shamsuddin AM, Elsayed AM, Ullah A. Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 1988; 9: 577-80.
40. Shamsuddin AM, Ullah A, Chakravarthy AK. Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. Carcinogenesis 1989; 10: 1461-3.
41. Shamsuddin AM, Ullah A. Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 1989; 10: 625-6.
42. Ullah A, Shamsuddin AM. Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis 1990; 11: 2219-22.
43. Nelson RL, Yoo SJ, Tanure JC, Andrianopoulos G, Misumi A. The effect of iron on experimental colorectal carcinogenesis. Anticancer Res 1989; 9: 1477-82.
44. Shivapurkar N, Tang ZC, Frost A, Alabaster O. A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. Cancer Lett 1996; 100: 169-79.
45. Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992; 13: 1509-12.
46. Challa A, Rao DR, Reddy BS. Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea. Carcinogenesis 1997; 18: 2023-6.
47. Jenab M, Thompson LU. Phytic acid in wheat bran affects colon morphology, cell differentiation and apoptosis. Carcinogenesis 2000; 21: 1547-52.
48. Thompson LU, Zhang L. Phytic acid and minerals: effect on early markers of risk for mammary and colon carcinogenesis. Carcinogenesis 1991; 12: 2041-5.
49. Norazalina NM, Hairuszah I, Norashareena MS. Anticancinogenic efficacy of phytic acid extracted from rice bran on azoxymethane-induced colon carinogenesis in rats. Exp Toxicol Pathol 2009 (in press).
50. Vucenik I, Tomazic VJ, Fabian D, Shamsuddin AM. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett 1992; 65: 9-13.
51. Jariwalla RJ, Sabin R, Lawson S, Bloch DA, Prender M, Andrews V, Herman ZS. Effects of dietary phytic acid (phytate) on the incidence and growth rate of tumors promoted in Fisher rats by a magnesium supplement. Nutr Res1988; 8: 813-27.
52. Ishikawa T, Nakatsuru Y, Zarkovic M, Shamsuddin AM. Inhibition of skin cancer by IP6 in vivo: initiation-promotion model. Anticancer Res1999; 19: 3749-52.
53. Gupta KP, Singh J, Bharathi R. Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 2003; 46: 66-72.
54. Lee HJ, Lee SA, Choi H. Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis. Asian Pac J Cancer Prev 2005; 6: 41-7.
55. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM. Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 1998; 18: 1377-84.
56. Hirose M, Ozaki K, Takaba K, Fukushima S, Shirai T, Ito N. Modifying effects of the naturally occurring antioxidants gammaoryzanol, phytic acid, tannic acid and n-tritriacontane-16, 18-dione in a rat wide-spectrum organ carcinogenesis model. Carcinogenesis 1991; 12: 1917-21.
57. Vucenik I, Zhang ZS, Shamsuddin AM. IP6 in treatment of liver cancer. II: intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 1998; 18: 4091-6.
58. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 2004; 10: 244-50.
59. Raina K, Rajamanickam S, Singh RP, Agarwal R. Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res 2008; 14: 3177-84.
60. Kolappaswamy K, Williams KA, Benazzi C, et al. Effect of inositol hexaphosphate on the development of UVB-induced skin tumors in SKH1 hairless mice. Comp Med 2009; 59: 147-52.
61. Vucenik I, Sakamoto K, Bansal M, Shamsuddin AM. Inhibition of rat mammary carcinogenesis by inositol hexaphosphate (phytic acid): a pilot study. Cancer Lett 1993; 75: 95-102.
62. Vucenik I, Yang GY, Shamsuddin AM. Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 1995; 16: 1055-8.
63. Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 1993; 14: 1975-7.
64. Wattenberg LW. Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res 1999; 19: 3659-61.
65. Shamsuddin AM, Baten A, Lalwani ND. Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. Cancer Lett 1992; 64: 195-202.
66. Deliliers GL, Servida F, Fracchiolla NS, et al. Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells. Br J Haematol 2002; 117: 577-87.
67. Sakamoto K, Venkatraman G, Shamsuddin AM. Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 1993; 14: 1815-9.
68. Weglarz L, Parfiniewicz B, Orchel A, Dzierzewicz Z. Antiproliferative effects of inositol hexaphosphate and verapamil on human colon cancer Caco-2 and HT-29 cells. Acta Poloniae Pharm 2006; 63: 443-5.
69. Shamsuddin AM, Yang GY, Vucenik I. Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 1996; 16: 3287-92.
70. Dorsey M, Benghuzzi H, Tucci M, Cason Z. Growth and cell viability of estradiol and IP-6 treated Hep-2 laryngeal carcinoma cells. Biomed Sci Instrum 2005; 41: 205-210.
71. Ferry S, Matsuda M, Yoshida H, Hirata M. Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkappaB-mediated cell survival pathway. Carcinogenesis 2002; 23: 2031-41, [Erratum appears in Carcinogenesis. 2003 Jan; 24(1): 149].
72. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 1995; 16: 1975-9.
73. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003; 24: 555-63.
74. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia (New York) 2004; 6: 646-59.
75. Vucenik I, Tantivejkul K, Zhang ZS, Cole KE, Saied I, Shamsuddin AM. IP6 in treatment of liver cancer. I: IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 1998; 18: 4083-90.
76. Somasundar P, Riggs DR, Jackson BJ, Cunningham C, Vona-Davis L, McFadden DW. Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer. J Surg Res 2005; 126: 199-203.
77. McMillan B, Riggs DR, Jackson BJ, Cunningham C, McFadden DW. Dietary influence on pancreatic cancer growth by catechin and inositol hexaphosphate. J Surg Res 2007; 141: 115-9.
78. Rizvi I, Riggs DR, Jackson BJ, Ng A, Cunningham C, McFadden DW. Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. J Surg Res 2006; 133: 3-6.
79. Arnold JT, Wilkinson BP, Sharma S, Steele VE. Evaluation of chemopreventive agents in different mechanistic classes using a rat tracheal epithelial cell culture transformation assay. Cancer Res 1995; 55: 537-43.
80. Babich H, Borenfreund E, Stern A. Comparative cytotoxicities of selected minor dietary non-nutrients with chemopreventive properties. Cancer Lett 1993; 73: 127-33.
81. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 1997; 57: 2873-8, [Erratum appears in Cancer Res 1997 Nov 15; 57(22): 5198].
82. Nickel KP, Belury MA. Inositol hexaphosphate reduces 12-O- tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase independent of protein kinase C isoform expression in keratinocytes. Cancer Lett 1999; 140: 105-11.
83. Yang GY, Shamsuddin AM. IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. Anticancer Res 1995; 15: 2479-87.
84. Tran HC, Brooks J, Gadwal S, et al. Effect of inositol hexaphosphate (IP6) on AIDS neoplastic Kaposi's sarcoma, iatrogenic Kaposi's sarcoma and lymphoma. Proc Am Assoc Cancer Res 40, 499. 2003; 40: 499.
85. Sakamoto K, Vucenik I, Shamsuddin AM. [3H]phytic acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. J Nutr 1993; 123: 713-720.
86. Vucenik I, Shamsuddin AM. [3H]inositol hexaphosphate (phytic acid) is rapidly absorbed and metabolized by murine and human malignant cells in vitro. J Nutr 1994; 124: 861-8.
87. Morrison HR, Mamarre E, Drazba J, Prestwich GD, Lindner DJ. Gene deletion if inositol hexakisphosphate kinase 2 predisposes to earodigestive tract carcinoma. Oncogene 2009; 28(25): 2383-92.
88. Grases F, Simonet BM, Vucenik I, Perello J, Prieto RM, Shamsuddin AM. Effects of exogenous inositol hexakisphosphate (InsP(6)) on the levels of InsP(6) and of inositol trisphosphate (InsP(3)) in malignant cells, tissues and biological fluids. Life Sci 2002; 71: 1535-46.
89. Grases F, Simonet BM, Vucenik I, et al. Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans. Biofactors 2001; 15: 53-61.
90. Muraoka S, Miura T. Inhibition of xanthine oxidase by phytic acid and its antioxidative action. Life Sci 2004; 74: 1691-700.
91. Rao PS, Liu XK, Das DK, Weinstein GS, Tyras DH. Protection of ischemic heart from reperfusion injury by myo-inositol hexaphosphate, a natural antioxidant. Ann Thorac Surg 1991; 52: 908-12.
92. Kamp DW, Israbian VA, Yeldandi AV, Panos RJ, Graceffa P, Weitzman SA. Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Toxicol Pathol 1995; 23: 689-95.
93. Sudheer KM, Sridhar RB, Kiran BS, Bhilegaonkar PM, Shirwaikar A, Unnikrishnan MK. Antiinflammatory and antiulcer activities of phytic acid in rats. Indian J Exp Biol 2004; 42: 179-85.
94. Singh A, Singh SP, Bamezai R. Modulatory influence of arecoline on the phytic acid-altered hepatic biotransformation system enzymes, sulfhydryl content and lipid peroxidation in a murine system. Cancer Lett 1997; 117: 1-6.
95. Porres JM, Stahl CH, Cheng WH, et al. Dietary intrinsic phytate protects colon from lipid peroxidation in pigs with a moderately high dietary iron intake. In: Proceedings of the Society for Experimental Biology & Medicine 1999; Vol. 221: pp. 80-6.
96. Nascimento NR, Lessa LM, Kerntopf MR, et al. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 2006; 103: 218-23.
97. Eggleton P. Effect of IP6 on human neutrophil cytokine production and cell morphology. Anticancer Res 1999; 19: 3711-5.
98. Baten A, Ullah A, Tomazic VJ, Shamsuddin AM. Inositol-phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression. Carcinogenesis 1989; 10: 1595-8.
99. Zhang Z, Song Y, Wang XL. Inositol hexaphosphate-induced enhancement of natural killer cell activity correlates with suppression of colon carcinogenesis in rats. World J Gastroenterol 2005; 11: 5044-6.
100. Cholewa K, Parfiniewicz B, Bednarek I, et al. The influence of phytic acid on TNF-alpha and its receptors genes' expression in colon cancer Caco-2 cells. Acta Poloniae Pharm 2008; 65: 75-9.
101. Morrison RS, Shi E, Kan M, et al. Inositolhexakisphosphate (InsP6): an antagonist of fibroblast growth factor receptor binding and activity. In vitro Cell Dev Biol Anim 1994; 30A: 783-9.
102. Vucenik I, Ramakrishna J, Tantivejkul K, Anderson L, Ramljak D. Inositol hexaphosphate (IP6) differentially modulates the expression of PKCd in MCF-7 and MDA-MB 231 cells. Proc Am Assoc Cancer Res 1999; 40: 653.
103. Vucenik I, Ramljak D. The contradictory role of PKCdelta in cellular signaling [comment]. Breast Cancer Res Treat 2006; 97: 1-2.
104. Solyakov L, Cain K, Tracey BM, et al. Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem 2004; 279: 43403-10.
105. Yang GY, Shamsuddin AM. A new murine monoclonal antibody, CMU10, as a marker for colonic carcinoma and precancerous conditions. Arch Pathol Lab Med 1995; 119: 454-7.
106. Vucenik I, Ramakrishna G, Tantivejkul K, Anderson LM, Ramljak D. Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation.[see comment]. Breast Cancer Res Treat 2005; 91: 35-45.
107. El-Sherbiny YM, Cox MC, Ismail ZA, Shamsuddin AM, Vucenik I. G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). Anticancer Res 2001; 21: 2393-403.
108. Roy S, Malikarjuna G, Ramasamy K, Singh RP, et al. p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 2009; 1166-73.
109. McFadden DW, Riggs DR, Jackson BJ, Cunningham C. Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. Oncol Rep 2008; 19: 563-6.
110. Karmakar S, Banik NL, Ray SK. Molecular mechanism of inositol hexaphosphate-mediated apoptosis in human malignant glioblastoma T98G cells. Neurochem Res 2007; 32: 2094-102.
111. Diallo JS, Betton B, Parent N,et al. Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors. Br J Cancer 2008; 99: 1613-22.
112. Xu Q, Kanthasamy AG, Reddy MB. Phytic acid protects against 6-OHDA and iron induced apoptosis in cell culture model of Parkinson's disease. FASEB J 2006; 20, A192.
113. Jagadeesh S, Banerjee PP. Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha. Biochem Biophys Res Commun 2006; 349: 1361-7.
114. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexaphosphate inhibits constitutive activation of NF- kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res 2003; 23: 3855-61.
115. Janus SC, Weurtz B, Ondrey FG. Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma. Laryngoscope 2007; 117: 1381-8.
116. Kapral M, Parfiniewicz B, Strzałka-Mrozik B, Zachacz A, Weglarz L. Evaluation of the expression of transcriptional factor NF-kappaB induced by phytic acid in colon cancer cells. Acta Pol Pharm 2008; 697-702.
117. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P, Shamsuddin AM. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 2004; 25: 2115-23.
118. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II: effects on integrins and focal adhesions. Anticancer Res 2003; 23: 3681-9.
119. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells. Anticancer Res 2003; 23: 3671-9.
120. Cheung JC, Salerno B, Hanakahi LA. Evidence for an inositol hexakisphosphate-dependent role for Ku in mammalian nonhomologous end joining that is independent of its role in the DNA-dependent protein kinase. Nucleic Acids Res 2008; 36: 5713-26.
121. Ra Yoon M, Nam SH, Young Kang M. Antioxidative and antimutagenic activities of 70% ethanolic extracts from four fungal mycelia-fermented specialty rices. J Clin Biochem Nutr 2008; 118-25.
122. Bozsik A, Kokeny S, Olah E. Molecular mechanisms for the antitumor activity of inositol hexakisphosphate (IP6). Cancer Genomics Proteomics 2007; 4: 43-51.
123. Howell A. The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 2008; 22: 615-23.
124. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643-58.
125. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000; 92: 1926-34.
126. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al. R. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004; 15: 885-90.
127. Carroll JS, Lynch DK, Swarbrick A, et al. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003; 63: 4322-6.
128. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001; 276: 40888-95.
129. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-54.
130. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004; 87: 167-80.
131. deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10: 8059-67.
132. Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Breast Cancer Res Treat 2003; 79: 301-12.
133. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008; 7: 1828-35.
134. Jariwalla RJ, Sabin R, Lawson S, Herman ZS. Lowering of serum cholesterol and triglycerides and modulations by dietary phytate. J Appl Nutr 1990; 42: 18-28.
135. Vucenik I, Podczasy JJ, Shamsuddin AM. Antiplatelet activity of inositol hexaphosphate (IP6). Anticancer Res 1999; 19: 3689-93.
136. Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) reduces risk for cancer and cardiovascular diseases. Period Biol 1997; 99: 25-30.
137. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18.
138. Hattori Y, Shi L, Ding W, Koga K. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release 2009.
139. Druzijanic N, Juricic J, Perko Z, Kraljevic D. IP-6 & Inositol: adjuvant to chemotherapy of colon cancer: a pilot clinical trial. Rev Oncol 2002; 4 (Suppl 1); 171.
140. Druzijanic N JJ, Perko Z, Kraljevic D. IP6 + Inositol as adjuvant to chemotherapy of colon cancer: Our clinical experience. Anticancer Res 2004; 24: 3474.
141. Juricic J, Druzijanic N, Perko Z, Kraljevic D, Ilic N. IP6 + Inositol in treatment of ductal invasive breast carcinoma: our clinical experience. Anticancer Res 2004; 24: 3475.
142. Sakamoto K, Suzuki Y. IP6 plus Inositol treatment after surgery and post-operative radiotherapy: report of a case: Breast cancer. Anticancer Res 2004; 24: 3617.
143. Sakamoto K. Long-term survival of a patient with advanced non-small cell lung cancer treated with Inositol Hexaphosphate (IP6) plus Inositol treatment combined with chemo-radiotherapy. Report of a case. Anticancer Res 2004; 24: 3618.
144. Shamsuddin AM. Metabolism and cellular functions of IP6: a review. Anticancer Res 1999; 19: 3733-6.
145. Maffucci T, Piccolo E, Cumashi A, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res 2005; 65: 8339-49.
146. Jariwalla RJ. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent. Anticancer Res 1999; 19: 3699-702.
147. Coppolino CA. Hexa-citrated phytate and process of preparation thereof. US Patent No 7,009,067.
148. Coppolino CA, Shamsuddin AM. Novel phytic citrate compounds and process for preparing the same. No 7, 517, 868.
149. Nyakuni G, Kikafunda, Muyonga, Kyamuhangire, Nakimbugwe, Ugen. Chemical and nutritional changes associated witht he development of the hard-to-cook defect in common beans. Int J Food Sci Nutr 2008; 59(7-8): 652-9.
150. Bohn L, Josefsen L, Meyer AS, Rasmussen SK. Quantitative analysis of phytate globoids isolated from wheat bran and characterization of their sequential dephosphorylation by wheat phytase. J Agric Food Chem 2007; 55: 7547-52.
151. Bohn L, Meyer AS, Rasmussen SK. Phytate: impact on environment and human nutrition: a challenge for molecular breeding. J Zhejiang Univ Sci B 2008; 9: 165-91.
152. Greiner R, Farouk AE, Carlsson NG, Konietzny U. myo-inositol phosphate isomers generated by the action of a phytase from a malaysian waste-water bacterium. Protein J 2007; 26: 577-84.
153. Doria GL, Calucci L, Pinzino C, Pilu R, Cassani E, Nielsen E. Phytic acid prevents oxidative stress in seeds: evidence from a maize (Zea mays L.) low phytic acid mutant. J Exp Bot 2009; 60(3): 967-78.